Industrial Technology Research Institute

Chih-Peng Liu

Chia-Mu Tu

Tsan-Lin Hu

Chih-Hung Chen

Kuo-Kuei Huang

Chrong-Shiong Hwang

Ming-Cheng Wei

Maggie J M Lu

Maggie Lu

Yi-Hsun Chen

Yuan-Jang Tsai

Min-Ying Lin

Ya-Chin Lo

Shuen-Hsiang Chou

Hsiang-Wen Tseng

Hsin-Hsin Shen

Hsiang-Fa Liang

Lain-Tze Lee

On Lee

Jui-Hsiang Chen

Ying-Chu Shih

Yen-Chun Chen

Meng-Nan Lin

Ting-Shou Chen

Felice Cheng

Yi-Ting Hsieh

Chia-Ching Chen

Chun-Min Liu

Yu-Wen Lo

Ling-Mei Wang

Yen-Fang Wen

Chiu-Lien Hung

Chih-Wei Fu

Shao-Chan Yin

Po-Hung Lai

Ching-Huai Ko

Tse-Min Teng

Jui-Wen Huang

Kuei-Tai Lai

Shih-Ta Chen

Chia-Wen Huang

Yi-Man Chou

Wan-Ru Chen

Yen-Jen Wang

Wen-Chia Huang

Chien-Lin Pan

Lain-tze Lee

A composition for improving the solubility of poorly soluble substances is provided. The composition includes about 40-99.5% by weight of cyclodextrin and/or derivatives thereof; about 0.05-10% by weight of at least one water-soluble polymer; and about 0.05-60% by weight of at least one water-soluble stabilizer.

Composition for improving the solubility of poorly soluble substances, use thereof and complex formulation containing thereof

A compound represented by Formula (I), a pharmaceutically acceptable salt or ester, hydrate, solvate or crystalline form thereof is provided: The compound represented by Formula (I) is a &#x3b2;-amino acid derivative, and in Formula (I) X is a single bond or O; Y is NH or C&#x2550;O; Z is C&#x2550;O, C&#x2550;S, NH, W is C or N; A is a single bond, O, OH, OCH, a heterocycle or N; Ris H or F; Ris H, F, OH, CF, CHOH, CHO or Ris H; n is 0 or 1; and m is 0 or 1.

Beta-amino acid derivative, kinase inhibitor and pharmaceutical composition containing the same, and method for performing an in vivo related application that benefits from the inhibition of a kinase

A compound of formula (I) or a pharmaceutically acceptable salt thereof is provided. In formula (I), Ar is indazole, 5-isoquinoline, 6-isoquinoline, or their N-oxide. X is &#x2014;C(&#x2550;Z)&#x2014;, wherein Z is N&#x2014;CN, NH, NR, NCOR, NCONRR, NCO-aryl, S, or O. Y and J are independently H, alkyl, aryl, aminoalkyl, &#x2014;NH, &#x2014;CN, &#x2014;OH, &#x2014;O-alkyl, &#x2014;O-aryl, &#x2014;COOH, &#x2014;COOR, &#x2014;CONHR, &#x2014;CONHCH-aryl, &#x2014;CONRCH-aryl, &#x2014;NHCOR, halogen, halogened alkyl, -alkyl-OR, -alkyl-ONO, alkyl-ONO, &#x2014;OCOOR, &#x2014;O(C&#x2550;O)-aryl, &#x2014;CHROH, &#x2014;CHOH, &#x2014;CHO(C&#x2550;O)-aryl, &#x2014;CHO(C&#x2550;O)&#x2014;R, &#x2014;CHRO(C&#x2550;O)-aryl, &#x2014;CHRO(C&#x2550;O)&#x2014;R, unsaturated carboxylic ester, substituted alkynyl, &#x2014;NHSOR, &#x2014;SOR, &#x2014;SONHR, or &#x2014;SONRR, or Y and J bond together to form a carbocylic or aromatic ring, wherein Rand Rare independently H, substituted C1-C6 alkyl, substituted aryl, cycloalkyl, alkylaryl, -alkyl-NRR, &#x2014;S(O)-(alkyl-NRR). R, Rand Rare H, C1-C6 alkyl, cycloalkyl, aryl, alkylaryl, alkylheteroaryl, alkylheterocycle, wherein any one thereof is optionally substituted with one or more of OH, NO, or NRR. 

Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same

Disclosed is an intralymphatic delivery method for treating lymphatic cancer using hyaluronan nanoparticles. These nanoparticles include a hyaluronic acid derivative and a platinum compound. The hyaluronan derivative includes hyaluronic acid, modified histidine and optionally one or more of a polymer or a C-Calkyl. The hyaluronic acid derivative may include linking group(s) that connect the polymer or the C-Calkyl to the hyaluronic acid. The platinum compound includes dichloro(1,2-diaminocyclohexane) platinum (DACHPt), cisplatin and oxaliplatin. This intralymphatic delivery method offers significant advantages for the use of platinum medicines in treating lymphatic cancer.

Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis

The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C-Calkane, wherein the modified histidine and the polymer or C-Calkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C-Calkane is about 0-40%.

Biomedical composition

The disclosure provides a pharmaceutical composition. The pharmaceutical composition includes a chitosan with palmitoyl groups and an active agent. According to another embodiment, the pharmaceutical composition can further include a gelling accelerating agent. According to an embodiment of the disclosure, the active agent of the disclosure can be administered in the form of a nano-drug, liposome, micelle, or microparticle.

Pharmaceutical composition

The disclosure is directed to a monohydrate crystalline form of 3-(5-(4-(3-fluoropropyl)piperazin-1-yl)benzimidazol-2-yl)-1-azaazulen-2-one, possessing diffraction peaks of about 12.9&#xb0;, 15.9&#xb0;, 17.9&#xb0;, 21.2&#xb0;, 22.9&#xb0;, 23.5&#xb0; and 24.5&#xb0;. Its preparation method and pharmaceutical composition thereof are also provided.

Monohydrate crystalline form of 3-(5-(4-(3-fluoropropyl)-piperazin-1-yl)benzimidazol-2-yl)-1-azaazulen-2-one, preparation, and pharmaceutical composition thereof

The invention is related to novel azulene-oxindole compounds having formula (I) shown below, wherein one of R, Rand Rrepresents a moiety of formula (II), each of Aand Aindependently is nitrogen, oxygen or sulfur, each of the others of R, R, R, R, R, R, R, R, R, R, R, R, R, and Ris as recited in the specification. The novel compound potentially inhibits multiple kinases and thus can be used to treat some disease like cancer or inflammatory. 

Azulene-oxindole compounds as multiple-kinase inhibitors and useful as anticancer agents

Growing community of inventors

Hsinchu, Taiwan

Chih-Peng Liu